4imprint Group (FOUR); withdraws recommendation to pay a final dividend in May 2020
4imprint provides a further update on the effect of the Covid-19 pandemic on its trading and operations. Since the last update on 19 March 2020, ‘Safer at Home’ or similar directives in nearly every state in the US and all of the UK have resulted in daily order counts that have been running at about 20% of the 2019 comparative.
Read more...CVC Credit Partners European Ops (CCPG); posts quarterly tender update
CVC Credit Partners published its annual circular in relation to its contractual quarterly tenders (Annual Circular). Given the current market conditions, the Board is expecting to reduce the maximum number of shares that may be tendered for purchase in respect of the tender in June 2020.
Read more...TBC Bank Group (TBCG); provides further update on COVID-19
TBC Bank’s CET1, Tier 1 and total CAR as of 31 March 2020 are estimated at 8.7%, 11.5% and 16.1%, respectively. These ratios remain well above NBG’s revised estimated minimum requirements of 7.0%, 8.8% and 13.4%, respectively.
Read more...Impact Healthcare REIT (IHR); posts trading and business update
Impact Healthcare REIT in its trading update announced that the group has signed a new revolving credit facility of £50m. The group confirmed that, as of 3 April 2020, it has received 100% of the rent due in respect of the forthcoming period from its tenants who operate care homes.
Read more...Mercia Asset Mgt (MERC); NVM VCTs raise £38.2m
Mercia Asset Management announced that the three Northern Venture Capital Trusts (NVM VCTs), which form a part of Mercia’s assets under management (AUM), have raised a total of £38.2m in new capital through the share offers launched in January 2020.
Read more...Gresham House Strategic (GHS); posts trading statement
The company announced an update for the financial year ended 31 March 2020. Unaudited 12-month NAV total return performance was -14.3% vs. FTSE Small Cap Index total return of -24.7% in the year from 1 April 2019 to 31 March 2020.
Read more...Ergomed (ERGO); announces second COVID-19 clinical study
Ergomed announced its support for a clinical development programme for namilumab, a monoclonal antibody therapy targeting granulocyte-macrophage colony stimulating factor (GM-CSF), for the treatment of patients with rapidly worsening COVID-19.
Read more...Tyman (TYMN); provides an update on the impact of the COVID-19
Tyman’s 2020 trading performance was in line with expectations until the middle of March. Since then, trading has progressively been impacted as increasingly stringent lockdowns have taken effect in the markets.
Read more...
ReNeuron Group (RENE); provides an update in light of the COVID-19
Following the outbreak of the COVID-19 pandemic, ReNeuron Group initiated a research programme focused on the potential utility of its proprietary exosomes as a delivery vehicle for viral vaccines.
Read more...Cenkos Securities (CNKS); expects to report small profit for FY20
Cenkos, which deferred its results announcement for the year ended 31 December 2019, expects its results to be in line with the trading update issued earlier. It expects to report a small profit for the year. Following the implementation of cost-saving steps introduced, the company expects its annual fixed cost base today to be more than £3.0m lower than in 2019.
Read more...